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IMMUNOBIOLOGY
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Human CD34 progenitor-derived
Langerhans-type dendritic cells (LCs)
are more potent stimulators of T-cell im-
munity against tumor and viral antigens
in vitro than are monocyte-derived DCs
(moDCs). The exact mechanisms have
remained elusive until now, however. LCs
synthesize the highest amounts of IL-
15R- mRNA and protein, which binds
IL-15 for presentation to responder lym-
phocytes, thereby signaling the phosphor-
ylation of signal transducer and activator
of transcription 5 (pSTAT5). LCs electropo-
rated with Wilms tumor 1 (WT1) mRNA
achieve sufficiently sustained presenta-
tion of antigenic peptides, which together
with IL-15R-/IL-15, break tolerance against
WT1 by stimulating robust autologous,
WT1-specific cytolytic T-lymphocytes
(CTLs). These CTLs develop from healthy
persons after only 7 days’ stimulation
without exogenous cytokines and lyse
MHC-restricted tumor targets, which in-
clude primary WT1 leukemic blasts. In
contrast, moDCs require exogenous
rhuIL-15 to phosphorylate STAT5 and at-
tain stimulatory capacity comparable to
LCs. LCs therefore provide a more potent
costimulatory cytokine milieu for T-cell
activation than do moDCs, thus account-
ing for their superior stimulation of MHC-
restricted Ag-specific CTLs without need
for exogenous cytokines. These data sup-
port the use of mRNA-electroporated LCs,
or moDCs supplemented with exogenous
rhuIL-15, as vaccines for cancer immuno-
therapy to break tolerance against self-
differentiation antigens shared by tu-
mors. (Blood. 2012;119(22):5182-5190)
Introduction
The dendritic cell (DC) hematopoietic lineage comprises heteroge-
neous subsets that share the capacity for potent initiation and
control of innate and adaptive immunity,1-5 but with sufficient
plasticity to orchestrate the quantity and quality of lymphocyte
responses. Indeed, defined subsets of human DCs generated with
cytokines in vitro also yield sufficient numbers with counterparts
in vivo to discern distinct consequences to T cells interacting with
one or another subtype.6-12
Human Langerhans-type DCs derived from CD34 hematopoi-
etic progenitor cells (HPCs) have consistently proven superior to
other conventional DC subsets as stimulators of CD8 cytolytic
T lymphocytes (CTLs) in vitro.9,11 This has led some investigators
to advocate inclusion of CD34 HPC-derived Langerhans cells
(LCs) in DC vaccines13,14 rather than relying solely on the more
commonly used monocyte-derived DCs (moDCs). The mecha-
nisms underlying LC potency have remained elusive, but IL-15 has
emerged as an important cytokine mediator.9,14 First, LCs’ potent
stimulation of CD8 CTLs occurs in the complete absence of
IL-12p70,9,15 which has proven more critical for the activation of
NK cells15 than for CD8 CTLs.9 Despite several shared functions,
IL-15 also has important contrasting roles with IL-2.16-18 IL-2
controls autoreactive T cells through their activation-induced
cell death, or apoptosis, and the maintenance and expansion of
Tregs. In contrast, IL-15 is critical to the generation of durable,
high-avidity, memory CD8 T cells, which could include
autoimmune populations with specificity for self-differentiation
tumor antigens.16-18
LCs secrete more IL-15 than any other conventional DC
subtype,9,15 but investigators have not previously identified IL-
15R- on the surface of LCs. This -subunit is required for
transport of IL-15 to the cell membrane to bind  (CD122) and
 (CD132) chains on responding lymphocytes. Only then is the
biologically active, heterotrimeric receptor-cytokine complex
complete, supporting subsequent lymphocyte signaling and
activation.16-18
We therefore undertook alternative approaches to define the
expression of IL-15R- by resident populations of primary human
LCs emigrating from cultured human epidermal sheets, as well as
LCs, dermal-interstitial DCs (DDC-IDCs), and moDCs generated
with recombinant human cytokines in vitro.9 Eliminating exposure
to IL-15 during DC development allowed comparison of tumor-
specific CTLs stimulated by LCs with those elicited by moDCs, as
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opposed to evaluating IL-15–induced moDCs with Langerhans-
like properties.19,20 This also facilitated evaluation of early T-cell
signaling events in response to LC or moDC stimulation, under
conditions of limited exogenous IL-15 or IL-15R- blockade.
Finally, we compared the capacity of LCs and moDCs to stimulate
CTLs from healthy persons in vitro against Wilms tumor protein 1
(WT1). Our findings link the expression of full-length antigen-
derived epitopes and the IL-15/IL-15R- complex by human LCs
with their capacity to overcome tolerance by potent stimulation of
CTLs against a self-differentiation tumor antigen like WT1. These
data provide a sound rationale for the evaluation of LCs, or moDCs
obligatorily supplemented with exogenous IL-15, in clinical trials
of active immunotherapy against human cancer.
Methods
Media and noncytokine supplements
Complete RPMI 1640 included 10mM HEPES, 1% penicillin/streptomycin
(Media Lab, Memorial Sloan-Kettering Cancer Center [MSKCC]), 50M
2-mercaptoethanol (Invitrogen), 1% L-glutamine (Invitrogen), and 1% or
10% volume/volume heat-inactivated, pooled normal human serum (NHS;
Atlanta Biologicals). X-VIVO 15 (BioWhittaker; Lonza Walkersville) was
used as manufactured without additives. All media and reagents were
endotoxin-free.
Human cells, media, and cytokines
Collection and use of human biospecimens adhered to protocols approved
by the Institutional Review and Privacy Board of Memorial Hospital,
MSKCC. Resident LCs were collected from excess skin obtained from
patients undergoing reconstructive surgery. Initially, sheets of full thickness
skin were cut into 4- to 6-mm pieces and partially digested in Dispase
(StemCell Technologies) at 4°C for 8 to 10 hours. Epidermal sheets were
then carefully peeled from the dermis, washed with cold PBS (MSKCC
Media Laboratory), and floated on 250 L of complete RPMI-10% NHS in
a 48-well tissue culture plate (Corning Life Sciences). To improve yield,
dermatomal sheets were obtained directly from reconstructive surgery
cases, from which multiple 8-mm punch biopsies were taken. These were
floated separately in 16-mm wells of a 24-well plate (Corning Life
Sciences) in 1 mL of complete RPMI-10% NHS. GM-CSF 1000 IU/mL
was added or not to maintain LC viability21 after either method to obtain
epidermal sheets, but no other cytokines were added for maturation or
activation. Epidermal sheets and cells were never exposed to xenogeneic
serum (eg, FCS). Cells that emigrated from the epidermis were collected
after 40 to 48 hours.
G-CSF–elicited CD34 HPCs from healthy donors undergoing leuko-
pheresis for allogeneic hematopoietic stem cell transplantation were used to
generate LCs and DDC-IDCs. These donors (before any GCSF exposure)
and healthy volunteers also provided PBMCs for the generation of moDCs.
Media, media supplements, cytokines, and commercial sources were
exactly as published9 (see erratum for correct FLT-3-ligand dose22).
In brief, however, CD34 HPCs were cultured in serum-free X-VIVO
15, supplemented with GM-CSF and TNF-, to which c-kit-ligand and
FLT-3-ligand were added for only the first 5 to 6 days of a 10- to 12-day
culture. In addition, for the respective generation of LCs or DDC-IDCs
from CD34 HPCs, either TGF- or IL-4 was added throughout the entire
culture period. For the generation of moDCs, tissue culture plastic adherent
CD14 monocytes were cultured in complete RPMI-1% NHS with
GM-CSF and IL-4 for 5 to 6 days. Each of these DC subtypes underwent
terminal maturation for an additional 48 hours using a combination of
TNF-, IL-1, IL-6, and prostaglandin E2. Each of the resulting DC
subtypes was uniformly CD14, CD11c, CD80, CD86bright, and CD83.
The CD34 HPC-derived LCs were unique among the other DC subtypes
for the absence of CD11b and asynchronous expression of Langerin
(CD207), which decreased with terminal activation and maturation.9
Although we did not specifically evaluate EpCAM, the phenotype of
CD34 HPC-derived LCs generated under similar culture conditions in
vitro has recently been shown to correspond to LCs isolated from human
epidermis.23 Both CD34 HPC-derived DDC-IDCs and moDCs expressed
CD11b but lacked Langerin.9 Only moDCs expressed CD91, the -2-
macroglobulin receptor, or significant amounts of CD52.9 We did not study
monocyte-derived LCs,24,25 which express little Langerin or Birbeck
granules and paradoxically secrete IL-12p70 in contrast to primary or
CD34 HPC-derived LCs.9,15,26
T cells were tissue culture plastic nonadherent PBMCs, further purified
by nonadherence and elution from nylon wool columns (Polysciences).
Purity was more than 95% based on CD3 expression.
All cells were used either fresh or thawed after cryopreservation.27
Viable recovery was more than 90%, without any compromise of phenotype
or activity.
Peptides
HLA-A*0201–restricted, native WT1 peptide (RMFPNAPYL126-134; Sigma-
Genosys)28 was used to verify antigen-specific CTL targeting. Synthetic
influenza matrix peptide (fluMP58-66 GILGFVFTL; Research Genetics,
Invitrogen) served as a positive recall antigen for HLA-A*0201–restricted
responses.
Immunofluorescence microscopy and analysis
Resident LCs from primary epidermal cell e´migre´s, cytokine-generated
CD34 HPC-derived LCs, and cytokine-differentiated moDCs, the latter
two subjected to immunomagnetic selection for high HLA-DR expression
(MiniMACS; Miltenyi Biotec), were cytocentrifuged (10 000 cells/slide) at
91.45g for 5 minutes (Cytospin 3; Shandon). Excess medium was aspirated,
after which the cells underwent fixation and permeabilization in 3%
paraformaldehyde for 20 minutes at 4°C, followed by air drying and storage
at room temperature or direct staining.
Immunofluorescent staining used polyclonal goat anti–human IL-
15R- (R&D Systems) followed by secondary rhodamine Red-X-
conjugated donkey anti–goat IgG (H  L) (Jackson ImmunoResearch
Laboratories). Resident epidermal LC e´migre´s were additionally stained
with monoclonal mouse anti–human HLA-DR (clone L243; BioLegend)
followed by AlexaFluor-647 rabbit anti–mouse IgG (H  L; Invitrogen).29
LCs and moDCs generated in vitro had already been purified by immuno-
magnetic selection for high HLA-DR expression and so did not require
additional anti–HLA-DR staining for identification. Actin staining of these
latter two populations used bodipy-conjugated phallacidin (Invitrogen).
Slides were visualized through an100 1.4 NA oil immersion lens with
an inverted Olympus IX-70 microscope (Delta Vision Image Restoration
Microscope; Applied Precision/Olympus) and Photometrics CoolSnap QE
camera. Alternatively, an inverted Leica LX microscope and a Leica DFC
350 FX camera were used. Serial optical sections (0.2 m; 40-60 sections)
were acquired for all labelings. Images were deconvoluted using DeltaVi-
sion SoftWoRx Version 3.4.4 software or Huygens 1.1.4 software (Montpel-
lier RIO Imaging). Fluorescent intensity per unit of volume of the
image-reconstructed cells yielded 3-dimensional units called voxels, which
were analyzed with ImageJ Version 1.41n (NIH). These were averaged from
the means of at least 20 cells in randomly selected fields per slide from
3 independent experiments.
Quantitative RT-PCR for measurement of IL-15R-mRNA
transcripts
Immunomagnetic selection for high HLA-DR expression (MiniMACS,
Miltenyi Biotec) provided purified populations of cytokine-generated,
immature and mature LCs, DDC-IDCs, and moDCs.9 Real-time RT-PCR
quantified IL-15R- mRNA transcripts by normalizing the average copy
number of IL-15R- cDNA to the 18S rRNA housekeeping cDNA within
each DC subtype. Assays-on-Demand Gene Expression probes for IL-
15R- (Hs00542604_m1, Applied Biosystems) detected mRNA transcripts
based on cDNA transcribed from 0.003 mg of Trizol (Invitrogen)–isolated
RNA. An 18S rRNA specific probe (Hs99999901_s1; Applied Biosystems)
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served as an internal housekeeping control. Thermal cycler parameters were
2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of 95°C for 15 seconds,
and 60°C for 1 minute. Relative gene expression data were calculated from
quadruplicate samples by normalizing the average copy number of IL-
15R- cDNA to the 18S rRNA housekeeping cDNA within each DC
subtype, then comparing that with immature moDCs, which had the lowest
transcript levels.
Phosphorylation of STAT5 in responder T cells
A total of 1  106 LCs or moDCs from HLA-A*0201–expressing donors
were pulsed with fluMP (fluMP58-66 GILGFVFTL, 10M) in 3 mL
complete RPMI in 6-well plates (Corning Life Sciences) for 1 hour at room
temperature, then cocultured with autologous T cells for 6 to 7 days9 to
generate fluMP-reactive T lymphoblasts. In other cases where HLA typing
was not available and Ag-specific responses were not required, concanava-
lin A 4 g/mL (conA; Sigma-Aldrich) was added to 106 PBMCs/mL
complete RPMI for 72 hours at 37°C to generate T lymphoblasts. T cells
were harvested and washed at the end of these culture periods, but a
modification for conA T lymphoblasts included washing in 10mM methyl-
-D-mannopyranoside (Calbiochem) to remove residual lectin. T cells were
then exposed to a glycine solution (pH 4) at 1  106 T cells/mL on ice for
1 minute to strip residual receptor-bound cytokines, after which the reaction
was stopped by the addition of 10 mL ice-cold PBS. Thereafter, the T cells
were resuspended in complete RPMI and rested for 1 to 2 hours at 37°C.
The absence of phosphorylated STAT5 was confirmed by flow cytom-
etry in these rested T cells before proceeding. For antigen-specific
responses, the rested but fluMP-reactive T cells were restimulated with
fresh, autologous LCs or moDCs pulsed de novo with fluMP, to which
nothing, rhuIL-15 (10 ng/mL; R&D Systems), or anti–IL-15R- (5 g/mL;
R&D Systems) was added. T/LC or moDC ratios were 10:1 for these
restimulations. Cell-free supernatants were also collected after the usual
48-hour maturation of LCs at 1  106 cells/3 mL/well of a 6-well tissue
culture plate (Corning Life Sciences) in inflammatory cytokines9,30 and
compared at 50% and 100% volume/volume with intact autologous LCs
(T/LC  10:1) for their capacity to mediate pSTAT5 in rested conA
T-cell blasts.
Cells and media were maintained at 37°C throughout. Cells were gently
pelleted at 300g for 20 seconds, incubated for 30 minutes at 37°C, then
gently repelleted. Cells were then fixed in 1.6% paraformaldehyde or
Cytofix (BD Biosciences), followed by permeabilization with ice-cold 90%
methanol, each for 10 minutes. Cells were washed in FACS buffer and then
stained with mouse anti–human CD3 FITC (Beckman Coulter) and either
rabbit anti–human pSTAT5 (Y694, Clone C11C5, Cell Signaling Technol-
ogy) and allophycocyanin-conjugated donkey anti–rabbit secondary anti-
body (Jackson ImmunoResearch Laboratories) or directly conjugated Alexa
Fluor 647 anti–human pSTAT5 (pY694, BD Biosciences). T cells were
analyzed for STAT5 phosphorylation (pSTAT5) after gating on viable
FITC-CD3 T cells (Cytomics FC500, Beckman Coulter; or LSR II, BD
Biosciences).
Electroporation of DCs by mRNA encoding WT1
An EcoRI insert encoding WT1 cDNA, derived from the pUC119 plasmid
(Riken Bioresource), was cloned into a pGEM-4Z vector (Promega). The
plasmid was transformed in Max Efficiency DH5- competent cells
(Invitrogen) and purified using a Plasmid Maxi Kit (QIAGEN). The
pGEM-4Z/WT1 plasmid was linearized with HindIII (New England
Biolabs) before mRNA transcription in vitro, which was performed with
SP6 RNA polymerase (mMessage mMachine SP6 kit; Ambion). Agarose
gel electrophoresis confirmed production of full-length capped mRNA, and
spectrophotometry measured mRNA concentration. Immature moDCs9
were electroporated on days 5 to 6 and immature LCs9 on days 10 to 11,
after washing and resuspending in OptiMEM (Invitrogen) at 20  106 cells/
mL. A total of 100 L of cell suspension was then mixed with 4 g of WT1
mRNA transcribed in vitro and electroporated in a 2-mm gap cuvette at
300 V for 500 s, using BTX ECM 830 square-wave electroporator (BTX
Harvard).31,32 Electroporated immature moDCs and LCs were recultured in
a combination of inflammatory cytokines for terminal maturation and
activation.9
CTL assays
Mature WT1 mRNA-electroporated autologous moDCs or LCs were
separately added in graded doses to triplicate wells of 1  105 T cells in a
96 round-bottomed well plate (Corning Life Sciences). Final volume was
100 L/well of complete RPMI-10% heat-inactivated, autologous serum.
Recombinant IL-15 (10 ng/mL; R&D Systems) was added only to moDC-
stimulated cultures where indicated.
Cytolytic activity exerted by responder T lymphocytes was assessed in
51Cr release or colorimetric assays. 51Cr-labeled targets included HLA-
A*0201 positive, WT1-expressing cell lines, HLA-A*0201 positive cell
lines pulsed or not with the HLA-A*0201 restricted WT1 peptide, or a class
I MHC-negative NK cell–sensitive cell line. Peripheral blood or marrow of
patients with acute leukemia provided primary blasts as targets for
colorimetric cytolytic assays, after semiquantitative PCR (Eppendorf)
confirmed WT1 expression using published sequences.28,33
By adding 5  103 51Cr-labeled target cells directly to replicate
microwells after only 7 days of stimulation by WT1 mRNA-electroporated
LCs or moDCs, total cytolytic activity generated per primary culture
condition could be compared based on 51Cr release into the supernatants
collected after 4 to 6 hours.9 Percent specific lysis was calculated in
standard fashion. Lysis of primary leukemic blasts required a colorimetric
CTL assay,34 which gave lower background than did spontaneous 51Cr
release.
Statistics
Replicate means from more than 3 independent experiments were averaged
and SEM calculated as the measure of variability. A stratified t test
(stratified by the effector/target or responder/stimulator ratio) was used for
the functional assays. The 2-sample t test was used for each comparison
within a given time point or condition for all other analyses.
Results
Mature LCs express significantly higher IL-15R-mRNA
transcripts and protein than do mature moDCs
Using flow cytometry, the surface expression of IL-15R- had been
previously documented on nonpermeabilized moDCs but not
LCs.15 This was despite LCs’ superior stimulation of CTLs
compared with moDCs9 and a known requirement for IL-15R- to
transport IL-15 to the cell surface for binding to  (CD122) and 
(CD132) chains on responder lymphocytes.18 This completes the
biologically active, heterotrimeric receptor-cytokine complex for
lymphocyte activation.16-18
We therefore evaluated primary tissue-resident LCs after emigra-
tion from epidermal sheets into suspension culture, which were
then cytocentrifuged onto glass slides, permeabilized, and immuno-
stained. Apart from mechanical perturbations, these LCs had no
exposure to other maturation stimuli, although we did compare
cells cultured with or without GM-CSF for enhanced LC viabil-
ity.21 Importantly, neither epidermal sheets nor LC e´migre´s were
ever cultured in FCS, which enhanced viability and activation state.
Immunofluorescent microscopy identified intracellular and cell
membrane expression of IL-15R- by the HLA-DR epidermal LC
e´migre´s (Figure 1). There was no significant difference in intensity
of expression between LCs exposed to GM-CSF or not, although
the GM-CSF–treated condition appeared to concentrate more of the
IL-15R- at the cell membrane.
Returning to purified populations of LCs expanded from
G-CSF–mobilized, CD34 HPCs,9 we first compared these with
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CD34 HPC-derived DDC-IDCs and moDCs. LC mRNA tran-
scripts for IL-15R-, quantified by real-time RT-PCR, were
significantly higher than transcripts in the other conventional DC
subtypes, especially after maturation (Figure 2A).
We then concentrated solely on CD34 HPC-derived LCs and
the more commonly used moDCs in cancer vaccines. Immunofluo-
rescent microscopy and digital imaging of immunostained, cytocen-
trifuged cells demonstrated that IL-15R- protein concentrated
along the LC surface membrane (Figure 2B), similar to what we
had observed with epidermal LC e´migre´s cultured in GM-CSF. In
contrast, moDCs exhibited a more generalized distribution
(Figure 2B). The overall density of IL-15R-was also significantly
higher on mature, activated CD34 HPC-derived LCs than on
mature moDCs (P  .0014; Figure 2C). These mature, activated
LCs therefore maintain both the largest pool of mRNA transcripts
and the highest protein levels of both intracellular and cell
membrane-associated IL-15R-, compared with other conven-
tional DC subsets.
LCs provide a more potent T-cell costimulatory cytokine
environment through endogenous IL-15 than do moDCs
Previous attempts to demonstrate a unique role for LC-derived
IL-15 in priming CD8 T cells documented inhibition after
LC blockade by anti–IL-15R-, but the inhibition was incom-
plete.14 Plausible explanations included the presence of CD4
T cells that secreted other cytokines supporting CD8 CTL
expansion, which were not blocked, or inadequate concentrations
of the blocking anti–IL-15R- without a positive control to
establish sufficient antibody dose. Other unmeasured factors could
also have contributed to CTL stimulation downstream of the initial
T-cell activation events, especially over two 7-day rounds of
stimulation in vitro that followed priming by peptide-pulsed LC or
moDC vaccines in vivo.
We therefore required a reporter tool for an IL-15–dependent
early T-cell activation event. Hence, we assessed phosphoryla-
tion of STAT5, which results from signaling by the IL-15–
heterotrimeric IL-15R complex via JAK3.35 We also used influenza
as a positive recall antigen to avoid any impediments to priming
against a self-differentiation tumor antigen. T cells were first
stimulated for 6 to 7 days by CD34 HPC-derived LCs or moDCs
presenting fluMP,9 then washed, resuspended, and rested for 1 to
2 hours. The absence of phosphorylated STAT5 was confirmed,
after which T cells were restimulated for 30 minutes with fresh,
mature LCs or moDCs, each pulsed de novo with fluMP, in the
presence or absence of exogenous rhuIL-15 or anti–IL-15R-. LCs
stimulated very strong phosphorylation of STAT5, with no biologic
advantage conferred by exogenous rhuIL-15 (Figure 3A-C). This
contrasted with moDCs, which had an absolute requirement for
exogenous rhuIL-15 to stimulate a comparably robust pSTAT5
response (Figure 3A-C). Anti–IL-15R- completely inhibited
phosphorylation of STAT5, whether IL-15 was provided endog-
enously by LCs or exogenously to moDCs (Figure 3A). Figure 3C
shows the percentage increase or decrease in fluMP-reactive T cells
with phosphorylated STAT5 after restimulation by LCs or moDCs
in the presence of either exogenous IL-15 or anti–IL-15R-,
relative to restimulation by LCs or moDCs alone. These experi-
ments showed that LCs produced enough IL-15 that the biologic
advantage conferred by exogenous IL-15 was limited to and
significantly greater for moDCs, which depended on this supplemen-
tal IL-15 to stimulate pSTAT5 in fluMP-reactive T cells. Con-
versely, the effect of anti–IL-15R- was significantly greater on
LCs, because of their endogenous IL-15 production, than it was on
moDCs. Finally, to prove the necessity for the complete
LC membrane-bound IL-15R-/IL-15 complex and to exclude the
possibility of soluble complexes mediating the observed effects, we
found that neither 50% nor 100% volume/volume supernatants
from activated and matured LCs reproduced the phosphorylation of
STAT5 in T cells stimulated by LCs themselves (Figure 3D).
LCs, but not moDCs, stimulate WT1-reactive CTLs in the
absence of exogenous rhuIL-15
We further challenged our model by comparing the capacity of
CD34 HPC-derived LCs with moDCs to stimulate CTLs in vitro
from healthy volunteers against WT1. This is a strongly conserved
self-differentiation antigen shared by many tumors, toward which
healthy persons should be tolerant.
LCs and moDCs underwent electroporation with WT1 mRNA
to achieve sustained Ag presentation of epitopes restricted to both
Figure 1. Human primary LCs express IL-15R-. (A) Epidermal sheets from
healthy skin were cultured in complete RPMI-10% NHS. GM-CSF 1000 IU/mL was
added or not to maintain LC viability.21 The cells recovered in culture after 40 to
48 hours were cytocentrifuged, fixed and permeabilized, and stained as indicated for
IL-15R- (red), HLA-DR (green), and 4,6-diamidino-2-phenylindole (blue nuclear
DNA stain). Scale bars represent 10 m. (B) At least 20 cells in randomly selected
fields from each donor/condition were evaluated to calculate the average voxels,
which represent digitalized 3-dimensional image data. Shown in the bar graph are the
averaged replicate means from 3 independent experiments 	 SEM. *P  .0254.
Error bar not shown for the condition without GM-CSF, as lower viability yielded
sufficient cells from only 2 independent experiments.
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class I and II MHC.36 We nevertheless limited these experiments to
persons expressing HLA-A*0201 to allow confirmation of class I
MHC restriction of the resulting CTL reactivity. After primary
stimulation in vitro without exogenous rhuIL-15 for only 7 days,
WT1 mRNA-electroporated LCs demonstrated potent stimulation
of autologous HLA-A*0201–restricted CTLs from healthy donors
against WT1-expressing tumor cell lines or against WT1 tumor
cell lines bearing the immunodominant HLA-A*0201–restricted
WT1 peptide (Figure 4A). Importantly, these CTLs also lysed
primary WT1-positive blasts from HLA-A*0201–positive patients
with acute myeloid leukemia (AML; Figure 4B). IL-15/IL-15R-
interaction was critical to LC stimulation of WT1-specific CTL
because blocking LCs with anti–IL-15R- during the 7-day
priming of T-cell responders completely abrogated lysis of a WT1
HLA-A*0201 control target (P  .001; Figure 4B). In contrast to
LCs, WT1 mRNA-electroporated moDCs, derived from the same
persons from whom LCs had been generated, did not stimulate any
WT1-specific CTLs without exogenous IL-15 (Figure 4C). Supple-
mentary IL-15, however, supported stimulation of cytolysis, which
closely approximated that stimulated by LCs providing endoge-
nous IL-15R-/IL-15 (Figure 4D).
Discussion
These results demonstrate that CD34 HPC-derived LCs use an
endogenous IL-15R-/IL-15–mediated mechanism, together with
effective presentation of a diverse array of antigenic peptides from
electroporated WT1 mRNA, to prime potent CTLs and break
tolerance against this self-differentiation tumor antigen. Impor-
tantly, these CTLs lyse not only tumor cell lines bearing WT1, but
also WT1-positive leukemic blasts from patients. LC activation of
T cells leads to IL-15R-/IL-15–mediated intracellular signaling
involving phosphorylation of STAT5 in the responder T cells. This
is in complete contrast with moDCs, which synthesize significantly
lower levels of IL-15R- and have an absolute requirement for
exogenous IL-15 to phosphorylate STAT5 or attain CTL stimula-
tory capacity approximating that of LCs.
CD34 HPC-derived LCs express the highest levels of mRNA
and protein for the IL-15R--receptor, compared with all other
conventional DC subtypes generated with cytokines in vitro.
Although our methods could not determine the amount of receptor
protein on the cytoplasmic versus external side of the cell
membrane, previous evaluations by flow cytometry of nonperme-
abilized cells using the same reagents had detected surface
IL-15R- on moDCs but not LCs,15 thus indicating that LCs must
reserve most or all of their IL-15R- intracellularly. This, together
with their large pool of mRNA for IL-15R-, should afford LCs
great flexibility in response to inflammation for rapid translation of
the functional receptor protein and optimal transport of bound
IL-15 to the cell surface and immune synapses with responder
lymphocytes. Digital imaging by fluorescent microscopy sup-
ports this conclusion, based on the much higher expression of
IL-15R- by CD34 HPC-derived LCs exposed to inflammatory
cytokines, compared with resident epidermal LC e´migre´s from
healthy skin. It is nevertheless important to note that, apart from
inflammatory maturation in vitro, the phenotype of CD34
HPC-derived LCs, generated under culture conditions similar to
our own, corresponds closely to LCs isolated from human
epidermis,23 but not to so-called monocyte-derived LCs.24,25
Until investigators develop the means to target LCs in situ and
selectively activate their migration to and stimulatory capacity
Figure 2. Mature CD34 HPC-derived LCs express the highest levels of
IL-15R- among all conventional DC subtypes. (A) Highly purified populations of
cytokine-generated, immature and mature moDCs, CD34 HPC-derived LCs, and
CD34 HPC-derived DDC-IDCs underwent quantification of IL-15R- mRNA by
real-time RT-PCR. Values were normalized to the housekeeping gene 18S rRNA
subunit. Data represent the averages of quadruplicate means 	 SEM from
3 independent experiments. *P  .019, immature LCs vs immature moDCs.
**P  .0005, immature LCs vs immature DDC-IDCs. ***P  .01, mature LCs vs all
other DC subtypes. (B) Cytocentrifuged, fixed, and permeabilized mature moDCs
and LCs were stained with polyclonal anti–IL-15R- followed by rhodamine Red-X–
conjugated donkey anti–goat IgG (red). F-actin control was stained by bodipy-
conjugated phallacidin (green), and nuclear DNA was stained with 4,6-diamidino-2-
phenylindole (DAPI; blue). Cells were examined by immunofluorescent microscopy.
Scale bars represent 10 m. (C) At least 20 cells in randomly selected fields from
each experiment were evaluated to calculate the average voxels, which represent
digitalized 3-dimensional image data. Shown in the bar graph are the averaged
replicate means from 3 independent experiments 	 SEM. *P  .0014 for IL-15R-.
P  not significant for F-actin.
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in draining lymph nodes, however, well-defined LCs generated
in vitro remain suitable candidates for cell-based vaccines.
moDCs express significantly less IL-15R-, even after inflam-
matory maturation, but seem capable of stimulating nearly
comparable cytolysis, at least in vitro, as long as exogenous
IL-15 is provided.
The critical role of IL-15R-/IL-15 for effective stimulation of
potent antitumor CTLs in vitro finally helps explain the superiority
of human LCs over moDCs. IL-15 promotes high-avidity CTLs,37
mitigates CD8 CTL apoptosis,14,38 and counters IL-2–induced
Treg development.14 These have useful applications to the induc-
tion of cellular immunity against self-differentiation tumor anti-
gens, toward which tolerance otherwise exists. Other common
-chain cytokines, such as IL-2 and IL-7, can also signal through
JAK3 and lead to pSTAT5. Reports in the literature support the
production of these and other cytokines by DCs and their subsets,
but there is great variation depending on the cytokine conditions
and type of serum exposure in culture.
Invoking a significant role for IL-2 in stimulating CTLs and
breaking tolerance against a self-differentiation Ag, such as WT1,
however, would contradict the well-established and contrasting
functions of IL-2 with IL-15, in terms of IL-2’s promoting
tolerance and countering autoimmunity by expansion of Tregs and
induction of apoptosis in activated T cells.17 IL-7 is also unlikely to
play a major role here given the cytokine-mediated down-
regulation of IL-7R- on antigen-reactive T cells.39,40 The more
compelling unknowns are the transcription factors activated and
genes expressed, which link enhanced cytotoxicity with antigen
presentation by LCs in the context of IL-15 signaling through
pSTAT5. Indeed, such molecular mechanisms are keys to under-
standing the relative affinities of different cytokines for different
JAK-STAT pathways and how IL-15 and other cytokines that
signal through a common, proximal JAK3-STAT5 pathway medi-
ate such distinct outcomes in responder lymphocytes.
mRNA electroporation, which facilitates processing and presen-
tation of multiple class I and II MHC-restricted epitopes from the
translated protein, also provides a significant advance over loading
single peptides on DCs.14 Furthermore, although our studies used
HLA-A*0201–expressing individuals to prove MHC restriction of
the stimulated T-cell responses, mRNA electroporation allows
individuals of any HLA type to process and present peptides
tailored to their own MHC molecules.
Our data do not exclude a possible role for moDC-based
vaccines supplemented with exogenous rhuIL-15. This obligatory
requirement for IL-15, however, may in part account for the
suboptimal results in many vaccine trials using moDCs in the
absence of adequate IL-15. On the other hand, there is a report of
successful remission induction of AML after vaccination with
moDCs electroporated with WT1 mRNA.41 LCs were not evalu-
ated or compared with moDCs in this trial. Most intriguing,
however, is that clinical responses correlated with elevated levels
of activated NK cells, given that myeloid leukemias are especially
Figure 3. CD34 HPC-derived LCs provide a more potent costimulatory cytokine environment through endogenous IL-15 for CTL activation than do moDCs.
(A) Cytokine-generated CD34 HPC-derived LCs or moDCs were pulsed with fluMP and recultured with purified autologous T cells already primed against fluMP
(responder/stimulator ratio  10:1). Cytokine or receptor blocking conditions are shown above each panel. Stimulation was stopped after 30 minutes at 37°C, and the
proportion of T cells that had phosphorylated STAT5 was measured by flow cytometry. One representative experiment of 3 is shown. (B) Using the gating for pSTAT5 in panel A,
the means from 3 independent experiments	 SEM are shown after stimulation by LCs or moDCs alone (P  .03; unpaired Student t test). (C) Again, using the pSTAT5 gating
in panel A, the change in percentage of pSTAT5 fluMP-reactive T cells, stimulated by either LCs or moDCs in the presence of IL-15 or anti–IL-15R-, relative to stimulation by
LCs or moDCs alone, is shown (n  3 independent experiments each, mean 	 SEM, P  .034 for the supplemental IL-15 condition, and P  .023 for the anti–IL-15R-
condition, comparing LCs vs moDCs by the unpaired Student t test). (D) The mean percentage 	 SEM of antigen-nonspecific, rested conA T lymphoblasts that expressed
pSTAT5 after restimulation by autologous LCs (n  4 independent experiments) or 50% or 100% volume/volume LC-free supernatants (n  5 independent experiments) was
determined by cytofluororaphy using the same gating strategy as in panel A. The paired t test yielded P 
 .02 for the intact LC stimulation versus either concentration of LC-free
supernatants, which were not significantly different from the negative control, T cells alone. ns indicates not significant.
HUMAN LCs USE IL-15 TO BREAK TOLERANCE AGAINST WT1 5187BLOOD, 31 MAY 2012  VOLUME 119, NUMBER 22  only.
For personal use at UNIVERSITAETSSPITAL on January 8, 2013. bloodjournal.hematologylibrary.orgFrom 
sensitive to NK cell-mediated lysis.42,43 Only moDCs, by provision
of IL-12p70, can stimulate NK cell reactivity.15 LCs secrete no
IL-12p70 but support NK cell viability via IL-15.9,15
The logistics are simpler to generate moDCs instead of LCs
from their respective precursors using recombinant cytokines in
vitro. Human clinical trials of rhuIL-15 are also beginning to
evaluate the effect of this cytokine administered directly in vivo
(#NCT01021059) or used in the production of peptide-loaded DC
vaccines (#NCT01189383). Before investigators embrace either
LCs, which provide endogenous IL-15, or moDCs supplemented
by or generated in the presence of rhuIL-15,19 an improved
understanding of the molecular mechanisms linking IL-15 signal-
ing via pSTAT5 to the development of cytolysis by CD34
HPC-derived LCs is warranted.
At this juncture, however, our data conclusively establish that
CD34 HPC-derived LCs synthesize significantly greater amounts
of IL-15R- mRNA and protein, as well as IL-15 itself,9,15
compared with other conventional DCs. LCs also provide endoge-
nous IL-15R-/IL-15, which induces transcriptional events medi-
ated through the JAK3/STAT5 pathway in responding effector
Figure 4. In the absence of exogenous rhuIL-15, only WT1 mRNA-electroporated CD34 HPC-derived LCs stimulate primary WT1-specific CTLs in vitro that kill
both immortalized and primary tumor cells. Cytokine-generated, CD34 HPC-derived LCs (A-B) and moDCs (C-D) from the same healthy, HLA-A*0201 donors were
electroporated with WT1 mRNA, matured by a combination of inflammatory cytokines, and then added in serial doses to triplicate microwells containing 1  105 autologous
T cells. Exogenous rhuIL-15 (10 ng/mL) was added to the primary cultures stimulated by moDCs only in panel D. A total of 5  103 51Cr-labeled target cells were added directly
to the primary culture microwells after only 7 days stimulation. 51Cr release was measured in the supernatants collected after 6 hours in panels A, C, and D. WT1 primary AML
blasts from patients expressing HLA-A*0201 were labeled with PKH-26 and evaluated as targets of CTLs stimulated by LCs in the absence of exogenous rhuIL-15 in panel B.
These response assessments used a flow cytometry-based assay whereby lysed targets took up an otherwise membrane impermeable DNA stain, TO-PRO-3. Specific lysis
was based on the frequency of PKH-26 TO-PRO3 relative to PKH-26 TO-PRO3 events. With either 51Cr or colorimetric labeling, specific lysis has been plotted against the
y-axes with respect to the conditions of primary stimulation shown along the x-axes. The cytolytic activity generated per primary culture condition could then be compared
between LC (A) and moDC stimulators, the latter without (C) or with (D) exogenous rhuIL-15 supplementation. (A,C-D) Data points are the averages 	 SEM of triplicate means
from each of 3 independent experiments using 3 different healthy donors. (A,C-D) Target cells were 697 cells (, HLA-A*0201, WT1 cell line); SKLY-16 cells pulsed with
HLA-A*0201-restricted WT1 peptide (ƒ; HLA-A*0201, WT1 cell line); unpulsed SKLY-16 cells (O; HLA-A*0201, WT1 cell line); and LCL721.221 cells (*; MHC class
I-negative, NK cell sensitive cell line). (B) One representative experiment of 3 independent experiments performed where 697 cells were targeted by T cells stimulated by LCs,
blocked (‚) or not () by anti–IL-15R- during T-cell priming. Primary AML blasts (; HLA-A*0201, WT1) proved susceptible, whereas NK cell-sensitive LCL721.221 cells
(*) proved resistant to CTLs stimulated by LCs in the absence of blocking anti–IL-15R-. *P 
 .01; **P 
 .001 for pairwise comparisons between either 697 or SKLY-16
WT1-pulsed cells versus LCL721.221 at the top 2 stimulator doses (A,D). **P 
 .001 for pairwise comparisons between 697 cells targeted by T cells primed by LCs blocked or
not with anti–IL-15R-, and for AML blasts versus LCL721.221, also at the top 2 stimulator doses (B).
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lymphocytes. moDCs achieve this only after provision of exog-
enous rhuIL-15. The impressive CTL stimulatory activity of human
LCs, electroporated with mRNA for sustained presentation of a
self-differentiation tumor antigen like WT1, should therefore
undergo further investigation in early phase clinical trials. These
could include either active immunization in vivo or adoptive
transfer of tumor antigen-specific CTLs expanded in vitro. Investi-
gators could also compare LC-based vaccines with rhuIL-15–
supplemented moDC vaccines or use the two in combination to
elicit both adaptive and innate cellular immunity, especially against
hematologic malignancies expressing WT1.
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